Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$37.48M
• Dividend Yield: N/A
• Average Volume (3M): 43.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: N/A
• EPS Growth: 10.49%
• Country: CA
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 66,933,290
• 10 Day Avg. Volume: 31,059
• 30 Day Avg. Volume: 43,967
• PEG Ratio: 0.88
• Price to Book (P/B): -21.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -53.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.16
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: C$0.53 ▼(-61.39% Downside)
• Action: Downgraded Date: 03/31/26
• Date: Action: Downgraded 03/31/26

The score is driven primarily by weak financial performance (no TTM revenue, ongoing losses, persistent cash burn, and negative equity). Technicals add further pressure with a clear downtrend and negative momentum. Valuation offers little support due to a negative P/E and no dividend yield data.

Positive Factors

Focused clinical-stage platform

Arch's concentrated DPEP‑1 inhibitor platform, LSALT (Metablok) program, and an extracellular histone antibody create a focused R&D funnel. A coherent platform strategy supports repeatable discovery, clearer go‑to‑market licensing plays, and the potential to generate multiple partnered assets across acute inflammatory indications.

Negative Factors

No product revenue and recurring losses

The company reports zero TTM revenue and a roughly $2.7M net loss, reflecting no internal product cash generation. Over the medium term this forces reliance on external financing or deals to fund trials, increasing dilution and creating sustained uncertainty around achieving self‑funding or progressing multiple programs without partner support.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or...

Read more

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or...

How the Company Makes Money

Arch Biopartners does not appear to be a commercial-stage company and, based on publicly available high-level disclosures, it has not indicated recurring product sales as a primary source of revenue. Its typical expected ways of generating revenue...

Read more

Arch Biopartners does not appear to be a commercial-stage company and, based on publicly available high-level disclosures, it has not indicated recurring product sales as a primary source of revenue. Its typical expected ways of generating revenue...

Arch Biopartners Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	2.12M	1.98M	964.68K	3.89M
Gross Profit	0.00	-1.66M	-129.00K	-503.00K	-150.00K
EBITDA	-1.29M	-3.53M	-336.00K	-101.00K	-77.02K
Net Income	-1.55M	-3.92M	-3.33M	-1.41M	-1.17M
Balance Sheet
Total Assets	104.53K	935.62K	1.17M	621.64K	2.67M
Cash, Cash Equivalents and Short-Term Investments	2.10K	2.97K	831.27K	506.35K	448.24K
Total Debt	2.84M	2.77M	5.02M	4.41M	5.16M
Total Liabilities	3.99M	5.28M	6.68M	5.09M	6.55M
Stockholders Equity	-3.88M	-4.35M	-5.51M	-4.47M	-3.88M
Cash Flow
Free Cash Flow	-1.58M	-2.33M	-234.08K	-1.08M	-2.98M
Operating Cash Flow	-1.58M	-2.33M	-234.07K	-1.08M	-2.98M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	1.58M	1.50M	559.00K	-421.37K	2.78M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 0.59, above the 50-day MA of 0.76, and above the 200-day MA of 1.23, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 36.14 is Neutral, neither overbought nor oversold. The STOCH value of 81.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCT	46 Neutral	C$42.49M	-0.56	-205.87%	―	―	62.01%
MSCL	44 Neutral	C$188.52M	-4.57	-51.42%	―	―	27.53%
MDNA	42 Neutral	C$44.67M	-4.40	-103.51%	―	―	54.74%
ARCH	39 Underperform	C$37.48M	-12.93	72.34%	―	―	10.49%